回顾性分析同期完成的尸体与活体供肾移植术前微量淋巴细胞毒( CDC)交叉配型实验检测结果与术后临床效果的内在关系。尸体供肾移植组术前CDC检测结果相对于活体供肾移植组显著增高(P<0．05)，术后受者死亡/肾丢失、排斥反应/延迟恢复发生率，尸体供肾移植组显著高于活体供肾移植组( P <0．05)。移植后在出现受者死亡/肾丢失、排斥反应/延迟恢复以及肺部感染这些不良事件时，尸体供肾移植组CDC检测结果在9%以上或者活体供肾移植组在4%以上的占比均显著高于未发生临床不良事件，两种不同来源的肾脏移植都应尽可能的选择术前CDC检测结果偏低的受者进行移植。%To analyze the effect of the complement-dependent cytotoxicity ( CDC) crossmatch and the internal rela-tionship with the clinical results. The results of the cadaveric donor before kidney transplantation surgery CDC test with respect to the living related donors transplantation were significantly higher (P<0. 05). After transplantation, for the death of the recipient ( graft loss ) , graft rejection ( incidence of delay recovery ) , cadaveric donor kidney transplantation group were significantly higher than that of living related donor kidney transplantation group ( P <0. 05). The deceased donor kidney transplantation in the event of the death(graft loss),graft rejection(delay recov-ery) and lung infections these adverse events CDC test resulted in more than 9%,which was significantly higher than the clinical adverse events that had not occurred;living donor kidney transplant recipients in the event of the death(graft loss),graft rejection(delay recovery) and lung infections these adverse events CDC test resulted in more than 4%,which was also higher than the clinical adverse event which had not occurred. The lower results of the preoperative CDC test should be selected for the two different sources transplant recipient of the kidney transplant.
展开▼
